Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001958606 | SCV002230881 | pathogenic | Immunodeficiency, common variable, 2 | 2021-08-12 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 1 of the TNFRSF13B gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in TNFRSF13B are known to be pathogenic (PMID: 16007087, 27123465). This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with TNFRSF13B-related conditions. Studies have shown that disruption of this splice site alters TNFRSF13B gene expression (PMID: 19629655). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV002492126 | SCV002800524 | likely pathogenic | Immunodeficiency, common variable, 2; Immunoglobulin A deficiency 2 | 2021-08-06 | criteria provided, single submitter | clinical testing |